Scientists, Whistle-Blowers and the Vanunu Affair

What should scientists and technicians working in a military research establishment do if they come across classified information that they believe should be made public? If they decide to publish information concerning a clear threat to world security, how should the international scientific community respond? Should it assist whistle-blowers if they are put on trial for breaking the country's secrecy laws? The plight of Mordechai Vanunu dramatically raises all these questions. Vanunu, a 33

Written byFrank Barnaby
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

What should scientists and technicians working in a military research establishment do if they come across classified information that they believe should be made public? If they decide to publish information concerning a clear threat to world security, how should the international scientific community respond? Should it assist whistle-blowers if they are put on trial for breaking the country's secrecy laws?

The plight of Mordechai Vanunu dramatically raises all these questions. Vanunu, a 33-year old Israeli, is standing trial in the Jerusalem District Court for treason, aggravated espionage and the collection of secret information with intent to harm Israel's security. Vanunu, a technician at Israel's nuclear power plant at Dimona, gave the London-based Sunday Times newspaper top-secret information about Israel's production of materials for use in nuclear weapons. The Times published the information on Oct. 5, 1986.

Using Vanunu's information one can calculate the possible size and quality of Israel's ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies